Our Pricing

What's The Difference Between Wegovy And Mounjaro Results?

Published on: June 03, 2026

Understanding the difference between Wegovy vs Mounjaro weight loss results UK is crucial when choosing your treatment pathway. Both medications are MHRA-licensed injectable therapies that have demonstrated significant efficacy in clinical trials, but they work through different mechanisms and produce distinct outcomes. At Cured Pharmacy, our UK-registered clinical team helps you navigate these options with transparent pricing and expert guidance.

Clinical Trial Results: Wegovy vs Mounjaro Weight Loss Outcomes

Mounjaro (tirzepatide) demonstrated superior weight loss in head-to-head comparisons with semaglutide-based treatments. In the SURPASS-2 trial, patients taking the highest dose of tirzepatide (15mg) achieved an average body weight reduction of 22.5% over 72 weeks, compared to 15.8% with semaglutide 1mg [1]. This represents a clinically meaningful difference for many patients seeking maximum efficacy.

Wegovy (semaglutide 2.4mg) remains highly effective in its own right. The STEP 1 trial showed participants lost an average of 14.9% of their initial body weight over 68 weeks, with nearly one-third achieving at least 20% weight reduction [2]. Both medications significantly outperform older weight loss treatments and lifestyle interventions alone.

It's important to note that individual results vary considerably. Your response depends on factors including baseline BMI, adherence to the dosing schedule, concurrent lifestyle modifications, and individual metabolic differences. These averages from clinical trials represent outcomes in controlled research settings with regular medical supervision.

How Mounjaro and Wegovy Work Differently

The key difference lies in their mechanism of action. Wegovy contains semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics a single natural hormone involved in appetite regulation and blood sugar control [2]. This proven pathway has been used successfully in diabetes management for over a decade before being licensed for weight management.

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed in the UK [1]. By activating both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors simultaneously, tirzepatide engages two complementary pathways. This dual action may explain the enhanced weight loss observed in clinical trials, though researchers continue to investigate the precise mechanisms.

What This Means for Your Treatment Journey

Both medications slow gastric emptying, reduce appetite, and improve feelings of fullness after eating. Most patients report decreased food cravings and smaller portion sizes within the first few weeks of treatment. The dual-action mechanism of Mounjaro may produce slightly faster initial weight loss in some individuals, though both require gradual dose escalation to minimise side effects.

Wegovy vs Mounjaro: Side Effects and Tolerability

Both medications share a similar side effect profile, as they work on overlapping biological pathways. The most common adverse effects are gastrointestinal: nausea, diarrhoea, constipation, and occasional vomiting [1][2]. These symptoms typically occur during dose escalation and often diminish as your body adjusts to the medication.

In clinical trials, approximately 44% of Mounjaro users experienced nausea compared to 40% of Wegovy users at therapeutic doses [1][2]. Discontinuation rates due to side effects were comparable between both treatments, ranging from 4-7% depending on the dose. Your prescriber will start you on the lowest dose and increase gradually over several months to improve tolerability.

Serious adverse events are rare but require immediate medical attention. These include signs of pancreatitis (severe abdominal pain), gallbladder problems, severe allergic reactions, or changes in vision. Both medications carry a boxed warning regarding thyroid C-cell tumours observed in animal studies, though no causal relationship has been established in humans [3].

Managing Common Side Effects

Our clinical team at Cured Pharmacy provides comprehensive guidance on minimising gastrointestinal symptoms. Strategies include eating smaller meals, avoiding high-fat foods, staying well-hydrated, and timing your injection appropriately. Most patients find side effects manageable and consider them acceptable given the significant weight loss benefits achieved.

Dosing Schedules and Treatment Progression

Both Wegovy and Mounjaro require once-weekly subcutaneous injections, typically administered on the same day each week. The injection can be given at any time of day, with or without meals, and rotated between the abdomen, thigh, or upper arm. This convenience factor makes both treatments practical for long-term use.

Wegovy follows a five-month dose escalation: starting at 0.25mg weekly, increasing to 0.5mg, then 1mg, 1.7mg, and finally the maintenance dose of 2.4mg [2]. This gradual titration helps your body adapt and reduces the likelihood of gastrointestinal side effects. If you experience persistent symptoms at any stage, your prescriber may slow the escalation.

Mounjaro uses a similar approach with four escalation steps: 2.5mg, 5mg, 10mg, and 15mg, each maintained for at least four weeks [1]. Some patients achieve their weight loss goals at the 10mg dose and don't require further increases. Your UK prescriber will adjust your dosing based on your response, tolerability, and clinical assessment at each stage.

Cost Comparison: Wegovy vs Mounjaro UK Pricing

At Cured Pharmacy, Mounjaro is available from £124.99 per month, subject to prescriber approval following your free online consultation. This transparent upfront pricing includes your medication, UK prescriber assessment, and discreet home delivery. We guarantee the lowest prices in the UK for genuine, licensed medications.

Treatment costs vary depending on your prescribed dose and duration. Most patients require 12-18 months of continuous treatment to achieve and maintain their weight loss goals. Your prescriber will discuss the expected treatment timeline during your consultation, considering your individual circumstances and weight loss targets.

Both medications represent a significant investment in your health, but clinical evidence demonstrates they're considerably more effective than older weight loss treatments. When comparing costs, consider the value of the clinical support provided, medication authenticity guarantees, and convenience of online prescribing services. Cured Pharmacy's superintendent pharmacist, Tarun Kumar (GPhC 2233073), ensures every prescription meets the highest UK standards.

Transparent Pricing and No Hidden Fees

Unlike some providers, we display exact pricing before you begin your consultation. There are no subscription lock-ins, hidden consultation fees, or unexpected charges. You'll know your monthly cost upfront, and you can pause or discontinue treatment at any time in consultation with your prescriber. We believe transparency builds trust and helps you make informed decisions about your healthcare.

Choosing Between Wegovy and Mounjaro: Clinical Considerations

Your UK prescriber will consider multiple factors when recommending between these treatments. Medical history plays a crucial role: certain conditions like personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 contraindicate both medications [3]. Previous experience with GLP-1 treatments, current medications, and specific health goals all influence the decision.

If you have type 2 diabetes alongside obesity, Mounjaro may offer additional glycaemic benefits due to its dual-receptor mechanism [1]. However, Wegovy has a longer track record in weight management specifically, with extensive real-world safety data accumulated since its approval. Some prescribers prefer starting with Wegovy due to this established evidence base.

Individual response varies significantly between patients. Some people achieve excellent results with Wegovy and experience minimal side effects, whilst others may respond better to Mounjaro's dual-action approach. If you don't achieve adequate weight loss (typically defined as 5% body weight reduction after 12 weeks at maintenance dose), your prescriber may recommend switching to the alternative medication [4].

At Cured Pharmacy, our clinical team takes time to understand your specific circumstances during the free online consultation. We consider your weight loss history, previous treatment attempts, lifestyle factors, and personal preferences. This individualised approach ensures you receive the most appropriate treatment for your needs, with ongoing support throughout your weight loss journey.

Scientific References

1. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): A Randomised, Open-Label, Phase 3 Trial. The Lancet, 398(10295), 64-77. https://doi.org/10.1016/S0140-6736(21)01324-6 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4mg Solution for Injection in Pre-filled Pen: Summary of Product Characteristics. GOV.UK. https://products.mhra.gov.uk/ [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for Managing Overweight and Obesity [TA875]. NICE Guidance. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment, lifestyle modifications, and individual metabolic response.